The clinical application of gene editing: Ethical and social issues

Kelly E. Ormond; Yvonne Bombard; Vence L. Bonham; Lily Hoffman-Andrews; Heidi Howard; Rosario Isasi; Kiran Musunuru; Kirsten A. Riggan; Marsha Michie; Megan Allyse

doi:10.2217/pme-2018-0155

The clinical application of gene editing: Ethical and social issues

Kelly E. Ormond, Yvonne Bombard, Vence L. Bonham, Lily Hoffman-Andrews, Heidi Howard, Rosario Isasi, Kiran Musunuru, Kirsten A. Riggan, Marsha Michie, Megan Allyse

Quantitative Health Sciences

Research output: Contribution to journal › Review article › peer-review

9 Scopus citations

Abstract

Gene-editing techniques have progressed rapidly in the past 5 years. There are already ongoing human somatic gene-editing clinical trials for multiple diseases. And there has been one purported scenario of human germline gene editing in late 2018. In this paper, we will review the current state of the technology, discuss the ethical and social issues that surround the various forms of gene editing, as well as review emerging stakeholder data from professionals, the 'general public' and individuals and families dealing with genetic diseases potentially treatable by gene editing.

Original language	English (US)
Pages (from-to)	337-350
Number of pages	14
Journal	Personalized Medicine
Volume	16
Issue number	4
DOIs	https://doi.org/10.2217/pme-2018-0155
State	Published - 2019

Keywords

CRISPR
clinical trials
ethics
gene editing
genome editing
germline gene editing
professional attitudes
public attitudes
somatic gene editing
stakeholder research

ASJC Scopus subject areas

Molecular Medicine
Pharmacology

Access to Document

10.2217/pme-2018-0155

Cite this

@article{08deb9078a734113b8899bb2ce193fba,

title = "The clinical application of gene editing: Ethical and social issues",

abstract = "Gene-editing techniques have progressed rapidly in the past 5 years. There are already ongoing human somatic gene-editing clinical trials for multiple diseases. And there has been one purported scenario of human germline gene editing in late 2018. In this paper, we will review the current state of the technology, discuss the ethical and social issues that surround the various forms of gene editing, as well as review emerging stakeholder data from professionals, the 'general public' and individuals and families dealing with genetic diseases potentially treatable by gene editing.",

keywords = "CRISPR, clinical trials, ethics, gene editing, genome editing, germline gene editing, professional attitudes, public attitudes, somatic gene editing, stakeholder research",

author = "Ormond, {Kelly E.} and Yvonne Bombard and Bonham, {Vence L.} and Lily Hoffman-Andrews and Heidi Howard and Rosario Isasi and Kiran Musunuru and Riggan, {Kirsten A.} and Marsha Michie and Megan Allyse",

note = "Publisher Copyright: {\textcopyright} 2019 Future Medicine Ltd.",

year = "2019",

doi = "10.2217/pme-2018-0155",

language = "English (US)",

volume = "16",

pages = "337--350",

journal = "Personalized Medicine",

issn = "1741-0541",

publisher = "Future Medicine Ltd.",

number = "4",

}

TY - JOUR

T1 - The clinical application of gene editing

T2 - Ethical and social issues

AU - Ormond, Kelly E.

AU - Bombard, Yvonne

AU - Bonham, Vence L.

AU - Hoffman-Andrews, Lily

AU - Howard, Heidi

AU - Isasi, Rosario

AU - Musunuru, Kiran

AU - Riggan, Kirsten A.

AU - Michie, Marsha

AU - Allyse, Megan

PY - 2019

Y1 - 2019

N2 - Gene-editing techniques have progressed rapidly in the past 5 years. There are already ongoing human somatic gene-editing clinical trials for multiple diseases. And there has been one purported scenario of human germline gene editing in late 2018. In this paper, we will review the current state of the technology, discuss the ethical and social issues that surround the various forms of gene editing, as well as review emerging stakeholder data from professionals, the 'general public' and individuals and families dealing with genetic diseases potentially treatable by gene editing.

AB - Gene-editing techniques have progressed rapidly in the past 5 years. There are already ongoing human somatic gene-editing clinical trials for multiple diseases. And there has been one purported scenario of human germline gene editing in late 2018. In this paper, we will review the current state of the technology, discuss the ethical and social issues that surround the various forms of gene editing, as well as review emerging stakeholder data from professionals, the 'general public' and individuals and families dealing with genetic diseases potentially treatable by gene editing.

KW - CRISPR

KW - clinical trials

KW - ethics

KW - gene editing

KW - genome editing

KW - germline gene editing

KW - professional attitudes

KW - public attitudes

KW - somatic gene editing

KW - stakeholder research

UR - http://www.scopus.com/inward/record.url?scp=85070213662&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070213662&partnerID=8YFLogxK

U2 - 10.2217/pme-2018-0155

DO - 10.2217/pme-2018-0155

M3 - Review article

C2 - 31331245

AN - SCOPUS:85070213662

SN - 1741-0541

VL - 16

SP - 337

EP - 350

JO - Personalized Medicine

JF - Personalized Medicine

IS - 4

ER -

The clinical application of gene editing: Ethical and social issues

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this